Literature DB >> 14981374

Prospective randomized controlled trial of fetal fibronectin on preterm labor management in a tertiary care center.

M Patrick Lowe1, Bridget Zimmerman, Wendy Hansen.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the effect of the rapid fetal fibronectin on the length of hospital stay and the use of preterm labor interventions in a tertiary care center. STUDY
DESIGN: Women who were seen in the Labor and Delivery Unit with symptoms of preterm labor were assigned randomly to receive fetal fibronectin (n=46 women) or to preterm labor management without fetal fibronectin (n=51 women). Physicians were not blinded to the result; groups were compared.
RESULTS: There was no difference between groups in demographic or obstetric characteristics, the hours spent in labor and delivery, the number of women who were admitted to the antepartum service, the length of stay, or medical interventions. When the results for women with a negative fetal fibronectin test were compared to women with a positive fetal fibronectin test, a significant difference was found in admissions to the antepartum service (P=.032) and the length of stay (P=.008).
CONCLUSIONS: A negative fetal fibronectin test was associated with fewer admissions to the antepartum ward and a shorter length of stay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981374     DOI: 10.1016/j.ajog.2003.08.041

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  The utility of fetal fibronectin in asymptomatic singleton and twin pregnancies with a cervical length ≤ 10 mm.

Authors:  Noelia Zork; Moti Gulersen; Anne Mardy; Caroline Pessel; Sara Brubaker; Joy Vink; Cynthia Gyamfi-Bannerman; Cande V Ananth
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-13

2.  Fetal fibronectin testing for reducing the risk of preterm birth.

Authors:  Vincenzo Berghella; Gabriele Saccone
Journal:  Cochrane Database Syst Rev       Date:  2019-07-29

3.  A high concentration of fetal fibronectin in cervical secretions increases the risk of intra-amniotic infection and inflammation in patients with preterm labor and intact membranes.

Authors:  Kyung Joon Oh; Roberto Romero; Jee Yoon Park; Jihyun Kang; Joon-Seok Hong; Bo Hyun Yoon
Journal:  J Perinat Med       Date:  2019-04-24       Impact factor: 1.901

4.  Cost-effectiveness of fibronectin testing in a triage in women with threatened preterm labor: alleviation of pregnancy outcome by suspending tocolysis in early labor (APOSTEL-I trial).

Authors:  Jolande Y Vis; Femke F Wilms; Martijn A Oudijk; Martina M Porath; Hubertina C J Scheepers; Kitty W M Bloemenkamp; Annemiek C Bolte; Jérôme Cornette; Jan B Derks; Johannes J Duvekot; Jim van Eyck; Anneke Kwee; Brent C Opmeer; Maria G van Pampus; Fred K Lotgering; Sicco A Scherjon; Krystyna M Sollie; Marc E A Spaanderman; Christine Willekes; Joris A M van der Post; Ben Willem J Mol
Journal:  BMC Pregnancy Childbirth       Date:  2009-09-01       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.